Last reviewed · How we verify

Atenolol/HCTZ/Trandolapril

University of Florida · FDA-approved active Small molecule

Atenolol/HCTZ/Trandolapril is a Antihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor) Small molecule drug developed by University of Florida. It is currently FDA-approved for Hypertension.

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: beta-blockade, diuresis, and ACE inhibition.

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: beta-blockade, diuresis, and ACE inhibition. Used for Hypertension.

At a glance

Generic nameAtenolol/HCTZ/Trandolapril
SponsorUniversity of Florida
Drug classAntihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor)
TargetBeta-1 adrenergic receptor, sodium-chloride cotransporter, angiotensin-converting enzyme
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Atenolol is a beta-1 selective antagonist that reduces heart rate and cardiac contractility. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that decreases blood volume and sodium reabsorption. Trandolapril is an ACE inhibitor that blocks angiotensin II formation, reducing vasoconstriction and aldosterone secretion. Together, these agents provide synergistic blood pressure reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atenolol/HCTZ/Trandolapril

What is Atenolol/HCTZ/Trandolapril?

Atenolol/HCTZ/Trandolapril is a Antihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor) drug developed by University of Florida, indicated for Hypertension.

How does Atenolol/HCTZ/Trandolapril work?

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: beta-blockade, diuresis, and ACE inhibition.

What is Atenolol/HCTZ/Trandolapril used for?

Atenolol/HCTZ/Trandolapril is indicated for Hypertension.

Who makes Atenolol/HCTZ/Trandolapril?

Atenolol/HCTZ/Trandolapril is developed and marketed by University of Florida (see full University of Florida pipeline at /company/university-of-florida).

What drug class is Atenolol/HCTZ/Trandolapril in?

Atenolol/HCTZ/Trandolapril belongs to the Antihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor) class. See all Antihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor) drugs at /class/antihypertensive-combination-beta-blocker-thiazide-diuretic-ace-inhibitor.

What development phase is Atenolol/HCTZ/Trandolapril in?

Atenolol/HCTZ/Trandolapril is FDA-approved (marketed).

What are the side effects of Atenolol/HCTZ/Trandolapril?

Common side effects of Atenolol/HCTZ/Trandolapril include Fatigue, Dizziness, Cough, Hyperglycemia, Hypokalemia, Bradycardia.

What does Atenolol/HCTZ/Trandolapril target?

Atenolol/HCTZ/Trandolapril targets Beta-1 adrenergic receptor, sodium-chloride cotransporter, angiotensin-converting enzyme and is a Antihypertensive combination (beta-blocker/thiazide diuretic/ACE inhibitor).

Related